Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 84
Filter
2.
Nature ; 2023 May 04.
Article in English | MEDLINE | ID: covidwho-2313338
3.
Nature ; 617(7960): 229-230, 2023 May.
Article in English | MEDLINE | ID: covidwho-2313337
6.
Nature ; 612(7941):614, 2022.
Article in English | ProQuest Central | ID: covidwho-2185685

ABSTRACT

Confronted with the prospect of stopping work, Cao realized that the methods he had specialized in could be used to study the antibodies triggered by infection with SARS-CoV-2. Cao - who leads much of the COVID-19 work in Xie's group - started his pandemic efforts by screening people who had recovered from COVID-19 for antibodies that could be used in treatment. Working with a Chinese drug company, the group picked two of the most potent infection-blocking, or neutralizing, antibodies and began trialling them in people with COVID-19.

10.
Nature ; 610(7931): 239-241, 2022 10.
Article in English | MEDLINE | ID: covidwho-2050306
12.
Nature ; 609(7928): 661-662, 2022 09.
Article in English | MEDLINE | ID: covidwho-2050295
13.
Nature ; 2022 Aug 11.
Article in English | MEDLINE | ID: covidwho-1991541
16.
Nature ; 606(7914): 452-455, 2022 06.
Article in English | MEDLINE | ID: covidwho-1890140
18.
Nature ; 2022 Mar 30.
Article in English | MEDLINE | ID: covidwho-1768798
20.
Nature ; 2022 Feb 03.
Article in English | MEDLINE | ID: covidwho-1671530
SELECTION OF CITATIONS
SEARCH DETAIL